EGFR and non-small cell lung carcinoma: AMT-562 also strongly synergized with VEGF- or EGFR-targeting mAbs bevacizumab and cetuximab, respectively, in CRC PDXs and with osimertinib or KRAS G12C inhibitor sotorasib in NSCLC PDX models [132].